Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Organogenesis Holdings Inc. - Class A (NQ:ORGO)

1.365 -0.045 (-3.19%)
Streaming Delayed Price Updated: 10:30 AM EDT, Sep 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Organogenesis Holdings Inc. - Class A

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Organogenesis (ORGO) Q2 2026 Earnings Call Transcript ↗
CMS policy changes drove 58% revenue decline, but sequential recovery signals stabilization. 
Via The Motley Fool
Topics Earnings
What's going on in today's session ↗
Via Chartmill
Which stocks are gapping on Friday? ↗
Via Chartmill
Top movers in Friday's pre-market session ↗
Via Chartmill
Organogenesis Holdings (NASDAQ:ORGO) Plunges 17% as Q2 Revenue and EPS Miss Estimates ↗
Via Chartmill
Organogenesis Holdings Inc (NASDAQ:ORGO) Soars on Stellar Q4 Earnings Beat ↗
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Organogenesis Q2 Earnings Call Highlights ↗
Organogenesis (NASDAQ:ORGO) reported a sharp year-over-year decline in second-quarter revenue as the skin substitute market continued to adjust to coverage and payment changes from the Centers for... 
Via MarketBeat
Topics Earnings
News headline image
Regenerative Medicine’s Next Chapter: Inside the Race to Make the Body Rebuild Itself
From Biotech Insider
Via GlobeNewswire
News headline image
The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It
From World Street Intelligence
Via GlobeNewswire
News headline image
Organogenesis (ORGO) Q1 2026 Earnings Transcript ↗
Organogenesis (ORGO) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Organogenesis Q1 Earnings Call Highlights ↗
Organogenesis (NASDAQ:ORGO) reported a sharp year-over-year revenue decline in the first quarter of 2026, with executives pointing to significant disruption in the skin substitute market following... 
Via MarketBeat
Topics Earnings
News headline image
Organogenesis Clears Major FDA Hurdle: Path to First Non-Surgical Biologic for Knee Osteoarthritis Widens
CANTON, Mass. — In a milestone development for the regenerative medicine sector, Organogenesis Holdings Inc. (Nasdaq: ORGO) announced today that it has successfully concluded a pivotal Type B meeting... 
Via MarketMinute
News headline image
Organogenesis (ORGO) Q4 2025 Earnings Transcript ↗
Organogenesis (ORGO) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Get insights into the top gainers and losers of Monday's after-hours session. ↗
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Unusual volume stocks in Monday's session ↗
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume. 
Via Chartmill
News headline image
What's going on in today's session ↗
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Keep an eye on the top gainers and losers in Friday's session. ↗
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
The market is buzzing with gapping stocks on Friday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Sanara MedTech Inc. Navigates Market Downturn Amidst "Undervalued" Consensus and Strategic Shifts
Dallas, TX – October 17, 2025 – Sanara MedTech Inc. (NASDAQ: SMTI), a company focused on surgical and chronic wound care, finds itself in the spotlight today as a bottom market performer, with its... 
Via MarketMinute
News headline image
Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO
From The DJS Law Group
Via Business Wire
News headline image
Organogenesis Holdings (ORGO) Battles Headwinds: Can This Regenerative Medicine Innovator Stage a Comeback?
Canton, MA – Organogenesis Holdings Inc. (NASDAQ: ORGO), a prominent player in the regenerative medicine sector, has recently endured a period of significant stock weakness, leaving investors... 
Via MarketMinute
Topics Fraud
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.